A breakthrough in bone cancer treatment for dogs is fueling hope for similar progress among a very different patient population.
Women suffering from breast cancer.
The two diseases may appear unrelated, but the
Encouraging data with the canine experiment is among several milestones that have
"We've built product candidates for multiple different types of cancers,"
The ongoing canine experiment, funded by
"She scientifically reasoned that dogs with bone cancer express the same antigen; therefore, she wanted to use our immunotherapy to see if it could have an effect on treating dogs with bone cancer/' O'Connor said.
Results showed the pet dogs that received the immunotherapy are living significantly longer than dogs with owners who chose not to participate in the study.
Of 11 dogs enrolled, about 80 percent lived at least 600 days. Dogs with osteosarcoma receiving standard treatment, including chemotherapy, have a median survival rate of nine months to a year. The lead bulldog treated in the
Based on that success,
"We are not a veterinary company, but we will opportunistically license that technology so that it can be fully exploited and explored in the hands of a veterinarian medicine company," O'Connor said.
Data from the canine experiment has accelerated
Closer to completion are
Because cancers associated with human papillomavirus are more widespread outside
Last month, the company signed a licensing deal with the Taiwanese company Global BioPharma to develop and commercialize ADXS-HPV in
O'Connor says that, while the company's technology has different uses, it derives from the same backbone. That's why
"We have a platform," O'Connor said. "Not just one drug, one disease. The platform has the ability to address multiple different types of diseases."
The biz in brief
NCIE Olnkatstage blotech compwiy spedauthg ii ananayofcaicerdrugs.
LEAD PRODUCTS: ADXS-HPV, which treats various cancers associated with human papillomavirus. The company is also developing beast and prostate cancer drugs.
STOCK: Trades mi Nasdaq under ADXS.
E-mail to: firstname.lastname@example.org
On Twitter: @biztzanki
Most Popular Stories
- Chobani Counters Competition With Expanded Lineup
- Twitter Offers App Install Ads
- What to Expect From an Amazon Smartphone
- Asia Seeks Obama's Assurance Over Spats
- Coachella's Young Audience a Marketers Paradise
- Nevada Range Showdown Draws Armed Supporters
- Putin: No Blocks to Boosting Relations With West
- NASA's Space Station Robonaut Finally Getting Legs
- National Energy Boom Blurs Political Battle Lines
- Report: Iran VP Says Row Over Reactor Resolved